Halozyme Therapeutics, Inc. (HALO) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Biotechnology
Wait for pullback to $63.37. Weak momentum — blocks BUY_NOW at $64.70. Engine's entry $63.37 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Leverage penalty (D/E 44.6): -1.5.
Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling subcutaneous delivery of biologics. Revenue comes from licensing fees, milestones, and royalties on 10 commercially approved partner products across 13... Read more
Wait for pullback to $63.37. Weak momentum — blocks BUY_NOW at $64.70. Engine's entry $63.37 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Leverage penalty (D/E 44.6): -1.5. Chart setup: Death cross, below all MAs, RSI 27, MACD bearish. Earnings in 0 days. Wait until post-earnings. Score 6.6/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-03-12Item 5.02HIGHDavid Ramsay appointed Interim CFO effective March 23, 2026. Previously served as Company CFO 2003-2009 and 2013-2015. No permanent CFO successor named; prior permanent CFO departure not described in this filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $63.37. Weak momentum — blocks BUY_NOW at $64.70. Engine's entry $63.37 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Leverage penalty (D/E 44.6): -1.5. Chart setup: Death cross, below all MAs, RSI 27, MACD bearish. Earnings in 0 days. Wait until post-earnings. Target $74.63 (+15.3%), stop $59.33 (−9.1%), Setup A.R:R 3.9:1. Score 6.6/10, moderate confidence.
Take-profit target: $74.63 (+17.7% upside). Target $74.63 (+15.3%), stop $59.33 (−9.1%), Setup A.R:R 3.9:1. Stop-loss: $59.33.
Leverage penalty (D/E 44.6): -1.5.
Halozyme Therapeutics, Inc. trades at a P/E of 25.0 (forward 6.5). TrendMatrix value score: 7.7/10. Verdict: Buy (Wait for Entry).
15 analysts cover HALO with a consensus score of 3.8/5. Average price target: $86.
What does Halozyme Therapeutics, Inc. do?Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling...
Halozyme is a biopharmaceutical company licensing its ENHANZE drug delivery technology to pharma partners, enabling subcutaneous delivery of biologics. Revenue comes from licensing fees, milestones, and royalties on 10 commercially approved partner products across 13 collaborations. Roche is the largest partner with 5 approved products.